Analysis of Leqembi's commercial potential and market outlook, with a focus on growth projections and investment ...

These trials, including those from companies like Eisai and UCB, have demonstrated robust target ... JMP Securities also reiterated a Buy rating on the stock with a $83.00 price target. TipRanks ...

Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...

BioArctic's Leqembi, the first FDA-approved Alzheimer's drug, faces EMA rejection but could see a stock surge with a positive ... drug as recent as last week. Eisai has already requested a ...

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys ...

JonesTrading analyst Soumit Roy has maintained their bullish stance on AVXL stock, giving a Buy rating on October 18. Soumit Roy has given his ...

AAII’s A+ Investor Value Grade is derived from a stock’s value score. The value score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, ...

At this time, I would like to welcome everyone to the Biogen third quarter 2024 earnings call and business update. [Operator ...

It has been a shaky time for healthcare stocks, but that only presents a buying opportunity. The Health Care Select Sector ...

Revolution Medicines, Inc. +25.20% +148.60% ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...